It is likely that a patent currently prohibits any generic Symlin from being manufactured. There are places claiming to sell it, but these medications are fake, substandard, and potentially dangerous. The earliest predictable date that a generic Symlin could become available is September 2015, when the next patent expires.
Generic Symlin: An OverviewSymlin® (pramlintide acetate) is a prescription medication that has been approved to treat both type 1 and type 2 diabetes.
Symlin is manufactured by Amylin Pharmaceuticals, Inc. At this time, no generic versions are approved for use or sale in the United States. Yet, if you search the Internet for "generic Symlin," you may find a number of companies selling it.
The fact is that these medicines are fake, substandard, and potentially dangerous. There may be generic Symlin available from another country, but there is really no way of knowing if you are getting genuine Symlin or not. Therefore, you should not buy any generic Symlin until an approved version is available.
When Will Generic Symlin Be Available?
The first patents for Symlin expired in March 2011 and September 2013. Yet, no generic versions are available. This strongly suggests that Symlin is protected from generic competition by one or more later-expiring patents, the next of which is set to expire in September 2015 and the last of which is set to expire in March 2019.
September 2015 is the next predictable date that a generic version of Symlin could become available. However, circumstances could shorten or extend the exclusivity period. This could include such things as other patents for specific Symlin uses or lawsuits.